RUTI® vaccine improves treatment of non-invasive bladder cancer by boosting immune response and providing clinical benefits
A clinical trial involving 40 patients, led by IrsiCaixa and IGTP and conducted at HUGTiP, confirms that the RUTI® vaccine, owned by Archivel Farma, enhances the effectiveness of the current treatment for non-muscle-invasive bladder cancer.
